SiRNA: Novel therapeutics from functional genomics

Biotechnology and Genetic Engineering Reviews

Volumn 30, Issue 1, 2014, Pages 1-30

  Joshi, B H ^a   Pachchigar, K P ^b  

^a ANAND AGRICULTURAL UNIVERSITY   (India)

^b SARDARKRUSHINAGAR DANTIWADA AGRICULTURAL UNIVERSITY   (India)

Author keywords

clinical trial; high throughput; in silico design; RNA interference; siRNA based therapeutic

Indexed keywords

DIAGNOSIS; RNA;

CLINICAL TRIAL; FUNCTIONAL GENOMICS; HIGH-THROUGHPUT; HUMAN GENOMES; IN SILICO DESIGN; IN-SILICO; RNA INTERFERENCE; SILICO DESIGN; SIRNA-BASED THERAPEUTIC; THERAPEUTIC TOOLS;

GENES;

15NP; AGN 745; ALN PCS 02; ALN TTR 01; ALN VSP 02; ANTISENSE OLIGONUCLEOTIDE; ASVASIRAN; ATU 027; BEVASIRANIB; CALAA 01; CAND 5; CEQ 508; EXCELLAIR; FOMIVIRSEN; MESSENGER RNA; MICRORNA; NUCB 1000; PEGAPTANIB; PF 655; PRO 040201; QPI 1007; RXI 109; SIMVASTATIN; SIRNA 027; SMALL INTERFERING RNA; SYL 040012; SYL 1001; TD 101; TKM 080301; TKM 100201; TKM PLK 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADVANCED CANCER; AMYLOIDOSIS; ASTHMA; COMPUTER MODEL; CONGENITAL PACHYONYCHIA; CYTOKINE RELEASE; CYTOMEGALOVIRUS RETINITIS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; EBOLA HEMORRHAGIC FEVER; FAMILIAL COLON POLYPOSIS; FUNCTIONAL GENOMICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC REGULATION; GENETIC SCREENING; GLAUCOMA; HEPATITIS B; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; INNATE IMMUNITY; ISCHEMIC OPTIC NEUROPATHY; LIVER CANCER; MOLECULAR RECOGNITION; NONHUMAN; OPTIC NERVE ATROPHY; PACHYONYCHIA; PHARMACOKINETICS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; VIRUS HEMORRHAGIC FEVER; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETICS; GENOMICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC THERAPY; GENOMICS; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING;

EID: 84904469311     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2014.921495     Document Type: Review

References (98)

1. Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T., Naik, N., BerDeja, A., ? Bhat, B. (2005). Fully 2?-modified oligonucleotiDe duplexes with improved in v itro potency and stability compared to unmodified small interfering RNA. Journal of Medicinal Chemistry, 48, 901-904. (Pubitemid 40270434)
2. Audouy, S. A., De Leij, L., Hoekstra, D., & Molema, G. (2002). In vivo characteristic s of cationic liposomes as Delivery vectors for gene therapy. Pharmaceutical Research, 19, 1599-1605. (Pubitemid 35305510)
3. Aza-Blanc, P., Cooper, C., Wagner, K., Batalov, S., Deveraux, Q., & Cooke, M. (2003). IDentif ication of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Molecular Cell, 12, 627-637. (Pubitemid 37222485)
4. Behlke, M.A. (2006). Progress towards in vivo use of siRNAs. Molecular Therapy, 13, 644-670.
5. Behlke, M.A. (2008). Chemical modification of siRNAs for in vivo use. OligonucleotiDes, 18, 305-319. (Pubitemid 352791344)
6. Bernstein, E., Caudy, A., Hammond, S., & Hannon, G. (2001). Role for a biDentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-366. (Pubitemid 32151243)
7. Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine, 11, 50-55. (Pubitemid 40215837)
8. BoDen, D., Pusch, O., Lee, F., Tucker, L., & Ramratnam, B. (2003). Human immunoDeficiency virus type 1 escape from RNA interference. Journal of Virology, 77, 11531-11535. (Pubitemid 37271651)
9. Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Oz, O., Mason, R., & Corey, D. (2004). Biodistribution of phosphodiester and phosphorothioate s iRNA. Bioorganic & Medicinal Chemistry Letters, 14, 1139-1143.
10. Bramsen, J. B., & Kjems, J. (2011). Chemical modification of small interfering RNA. Methods Mol. Biol., 721, 77-103.
11. Burnett, J. C., & Rossi, J. (2012). RNA-based therapeutics: Current progress and future prospects. Chemistry & Biology, 19, 60-71.
12. Burnett, J. C., Rossiand, J. J., & Tiemann, K. (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology Journal, 6, 1130-1146.
13. Castanotto, D., & Rossi, J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457, 426-433.
14. Celotto A.M.,Graveley B.,2002, Exon-specific RNAi: A tool for dissecting the functional releVance of alternative splicing,RNA,8,718-724. (Pubitemid 34620449)
15. Chang, E., Zhu, M., & Drezek, R. (2007). Novel siRNA-based molecular beacons for dual imaging and therapy. Biotechnology Journal, 2, 1-5.
16. Chien, P. Y., Wang, J., Carbonaro, D., Lei, S., Miller, B., Sheikh, S., ? Ahmad, I. (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA Delivery in vitro and in vivo. Cancer Gene Therapy, 12, 321-328. (Pubitemid 40315192)
17. Chollet, P., Favrot, M., Hurbin, A., & Coll, J. (2002). SiDe-effects of a systemic injection of linear polyethylenimine-DNA complexes. The Journal of Gene Medicine, 4, 84-91. (Pubitemid 40277159)
18. Choung, S., Kim, Y., Kim, S., Park, H., & Choi, Y. (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochemical and Biophysical Research Communications, 342, 919-927. (Pubitemid 43320485)
19. Cob urn, G., & Cullen, B. (2003). siRNAs: A new wave of RNA-based therapeutics. Journal of Antimicrobial Chemotherapy, 51, 753-756. (Pubitemid 36503408)
20. Couzin, J. (2002). Breakthrough of the year: Small RNAs make big splash. Science, 298, 2296-2297.
21. Das, A. T., Brummelkamp, T., Westerhout, E., Vink, M., Madiredjo, M., Bernards, R., & Berkhout, B. (2004). Human immunoDeficiency virus type 1 escapes from R NA interferencemediated inhibition. Journal of Virology, 78, 2601-2605. (Pubitemid 38228957)
22. DasGupta, R., & Perrimon, N. (2004). Using RNAi to catch Drosophila genes in a web of interactions: Insights into cancer research. Oncogene, 23, 8359-8365. (Pubitemid 39540717)
23. Dass, C. R. (2002). Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in vivo. Journal of Pharmacy and Pharmacology, 54, 593-601. (Pubitemid 34456018)
24. Davidson, B. L. , & McCray, P. (2011). Current prospects for RNA interference-based therapies. Nature Reviews Genetics, 12, 329-340.
25. De Fougerolles, A., Manoharan, M., Meyers, R., & Vornlocher, H. (2005). R NA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymology, 392, 278-296. (Pubitemid 40092520)
26. De Fougerolles, A., Vornlocher, H., Maraganore, J., & Lieberman, J. (2007). Inter fering with disease: A progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery, 6, 443-453. (Pubitemid 47064567)
27. Dorsett, Y., & Tuschl, T. (2004). siRNAs: Applications in functional genomics and potential as therapeutics. Nature Reviews Drug Discovery, 3, 318-329. (Pubitemid 38499759)
28. Dykxhoorn, D. M., & Lieberman, J. (2006). Knocking down disease with siRNAs. Cell, 126, 231-235. (Pubitemid 44092975)
29. Eckstein, F. (2002). Developments in RNA chemistry, a personal view. Biochimie, 84, 841-848. (Pubitemid 35422910)
30. Elbashir, S. M., LenDeckel, W., & Tuschl, T. (2001). RNA interference is mediated by 21-and 22-nucleotiDe RNAs. Genes & Development, 15, 188-200. (Pubitemid 32107664)
31. Elbashir, S. M., Martinez, J., Patkaniowska, A., LenDeckel, W., & Tuschl, T. (2001). Functional anatomy of siRNAs for mediating efficie nt RNAi in Drosophila melanogaster embryo lysate. The EMBO Journal, 20, 6877-6888. (Pubitemid 33134217)
32. Faustino, N., & Cooper, T. (2003). Pre-mRNA splicing and human disease. Genes & Development, 17, 419-437. (Pubitemid 36258756)
33. Fire, A., Xu, S., Montgomery, M., Kostas, S., Driver, S., & Mello, C. (1998). Potent and specific genetic interference by double-stranDed RNA in Caenorhabditis elegans. Nature, 391, 806- 811. (Pubitemid 28099681)
34. Gaglione, M., & Messere, A. (2010). Recent progress in chemically modified siRNAs. Mini Reviews in Medical Chemistry, 10, 578-595.
35. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H., & Chen, J. (2004). Inhibition of influenza virus production in virus-infected mice by RNA interference. Proceedings of the National AcaDemy of Sciences, 101, 8676-8681. (Pubitemid 38745830)
36. Grimm D.,Streetz K.,Jopling C.,Storm T.,PanDey K.,Davis C.,Marion P.,Salazar F.,Kay M.,2006,Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways, Nature,441,537-541. (Pubitemid 44050158)
37. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., ? Fischer, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunoDeficiency. New England Journal of Medicine, 348, 255-256. (Pubitemid 36077924)
38. Haussecker, D. (2012). The business of RNAi therapeutics. Molecular Therapeutics Nuclei Acids, 2, 1-12.
39. He, L., & Hannon, G. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics, 5, 522-531. (Pubitemid 38868508)
40. Holen, T., Amarzguioui, M., Babaie, E., & Prydz, H. (2003). Similar behaviour of single-s trand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Research, 31, 2401-2407. (Pubitemid 37442108)
41. Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., ? Hartmann, G. (2005). Sequence-specific potent induction of IFN by short interfering RNA in plasmacytoid Dendritic cells through TLR7. Nature Medicine, 11, 263-270. (Pubitemid 40460553)
42. Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J.,? Hall, J. (2005). Design of a genome-wiDe siRNA library using an artificial neural network. Nature Biotechnology, 23, 995-1001. (Pubitemid 41114034)
43. Hu-LieskoVan, S., HeiDel, J., Bartlett, D., Davis, M., & Triche, T. (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral Delivery of small interfering RNA inhibits tumor growth in a murine moDel of m etastatic Ewing';s sarcoma. Cancer Research, 65, 8984-8992. (Pubitemid 41377390)
44. Judge, A. D., Sood, V., Shaw, J., Fang, D., McClintock, K., & Maclachlan, I. (2005). SequenceDepenDent stimulation of the mammalia n innate immune response by synthetic siRNA. Nature Biotechnology, 23, 457-462. (Pubitemid 41724921)
45. Kariko, K., Bhuyan, P., Capodici, J., & Weissman, D. (2004). Small interfering RNAs mediate sequence-inDepenDent gene suppression and induce immune activation by signaling through toll-like receptor 3. The Journal of Immunology, 172, 6545-6549. (Pubitemid 38669088)
46. Kenski, D. M., Butora, G., Willingham, A. T., Cooper, A. J., Fu, W., Qi, N., ? Flanagan, W. M. (2012). siRNA-optimized modifications for enhanced in vivo activity. Molecular Therapy-Nucleic Acids, 1, e5, doi:10.1038/mtna.2011.4
47. Ketting, R. F., Fischer, S., Ber nstein, E., Sijen, T., Hannon, G., & Plasterk, R. (2001). Dicer functions in RNA interference and in synthesis of small RNA involved in Developmental timing in C. elegans. Genes & Development, 15, 2654-2659. (Pubitemid 32988876)
48. Khvorova , A., Reynolds, A., & Jayasena, S. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216. (Pubitemid 37329584)
49. Kim, D. H., Behlke, M., Rose, S., Chang, M., Choi, S., & Rossi, J . (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nature Biotechnology, 23, 222-226. (Pubitemid 40255333)
50. Kim, D. H., & Rossi, J. (2007). Strategies for silencing human disease using RNA interference. Nature Reviews Genetics, 8, 173-184.
51. Layzer, J. M., McCaffrey, A., Tanner, A., Huang, Z., Kay, M., & Sullenger, B. (2004). In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766-771. (Pubitemid 38529739)
52. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S., & Shen, Y. (2005). Evaluating hypoxia-inducible factor-1 as a cancer therapeutic target via inducible RNA interf erence in vivo. Cancer Research, 65, 7249-7258. (Pubitemid 41161256)
53. Lin, X., Ruan, X., AnDerson, M., McDowell, J., Kroeger, P., Fesik, S., & Shen, Y. (2005). siRNA-mediated off-target gene silencing trigger ed by a 7 nt complementation. Nucleic Acids Research, 33, 4527-4535. (Pubitemid 41222567)
54. Liu, J., Carmell, M., Rivas, F., MarsDen, C., Thomson, J., Song, J., ? Hannon, G. (2004). Argonaute2 is the catalytic en gine of mammalian RNAi. Science, 305, 1437-1441. (Pubitemid 39167657)
55. Liu, Q., Rand, T., Kalidas, S., Du, F., Kim, H., Smith, D., & Wang, X. (2003). R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway. Science, 301, 1921-1925. (Pubitemid 37221400)
56. Lu, P. Y., Xie, F., & Woodle, M. (2003). siRNA-mediated antitumorgenesis for drug target validation and therapeutics. Current Opinion in Molecular Therapeutics, 5, 225-234. (Pubitemid 37185340)
57. Ma Z.,Li J.,He F.,Wilson A.,Pitt B.,Li S.,2005, Cationic lipids enhance siRNA-mediated interferon response in mice, Biochemical and Biophysical Research Communications,330,755-759. (Pubitemid 40462151)
58. Manoharan, M . (1999). 2-Carbohydrate modifications in antisense oligonucleotiDe therapy: importance of conformation, configuration and conjugation. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1489, 117-130.
59. Manoharan, M. (2002). OligonucleotiDe conjugates as potential antisense drugs with improved uptake, biodistribution, targeted Delivery, and mechanism of action. Antisense and Nucleic Acid Drug Development, 12, 103-128. (Pubitemid 34627605)
60. Marques, J. T., & Williams, B. (2005). Activation of the mammalian immune system by siRNAs. Nature Biotechnology, 23, 1399-1405. (Pubitemid 41679392)
61. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., & Tuschl, T. (2002). Single-stranDed antisense siRNAs guiDe target RNA cleavage in RNAi. Cell, 110, 563-574. (Pubitemid 35247837)
62. Matranga, C., Tomari, Y., Shin, C., Bartel, D., & Zamore, P. (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620. (Pubitemid 41608464)
63. McCaffrey, A. P., Meuse, L., Pham, T., Conklin, D., Hannon, G., & Kay, M. (2002). Gene expression: RNA interference in adult mice. Nature, 418, 38-39. (Pubitemid 34742563)
64. McManus, M. T., Haines, B., Dillon, C., Whitehurst, C., Van Parijs, L., Chen, J., & Sharp, P. A. (2002). Small interfering RNA-mediated gene silencing in T lymphocytes. The Journal of Immunology, 169, 5754-5760. (Pubitemid 35291677)
65. Meister, G., & Tuschl, T. (2004). Mechanisms of gene silencing by double-stranDed RNA. Nature, 431, 343-349. (Pubitemid 39265674)
66. Morrissey, D. V., Lockridge, J., Shaw, L., Blanchard, K., Jensen, K., Breen, W., ? Polisky, B. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified s iRNAs. Nature Biotechnology, 23, 1002-1007. (Pubitemid 41114035)
67. Nagy, P., Arndt-Jovin, D., & Jovin, T. (2003). Small interfering RNAs suppress the expression of endogenous and GFP-fused epiDermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Experimental Cell Research, 285, 39-49. (Pubitemid 36390154)
68. Naito, Y., Yoshimura, J., Morishita, S., & Ui-Tei, K. (2009). siDirect 2.0: updated software for Designing functional siRNA with reduced seed-DepenDent off-target effect. BMC Bioinformatics, 10, 392-399.
69. Nattanan, T., & Thienprasert, P. (2012). Overview of RNA interference therapeutics. Songklanakarin Journal of Science and Technology, 34, 293-301.
70. Ntambi, J. M., Miyazaki, M., Stoehr, J., Lan, H., Kendziorski, C., YanDell, B., ? Attie, A. (2002). Loss of stearoyl-CoA Desaturase-1 function protects mice against adiposity. Proceedings of the National AcaDemy of Sciences, 99, 11482-11486. (Pubitemid 34920951)
71. Opalinska, J. B., & Gewirtz, A. (2002). Nucleic-acid therapeutics: Basic principles and recent applications. Nature Reviews Drug Discovery, 1, 503-514. (Pubitemid 37361504)
72. Pei, Y., & Tuschl, T. (2006). On the art of iDentifying effective and specific siRNAs. Nature Methods, 3, 670-676. (Pubitemid 44275732)
73. Poulin, G., Nandakumar, R., & Ahringer, J. (2004). Genome-wiDe RNAi screens in Caenorhabditis elegans: Impact on cancer research. Oncogene, 23, 8340-8345. (Pubitemid 39540714)
74. Raoul, C., Abbas-Terki, T., Bensadoun, J., Guillot, S., Haase, G., Szulc, J., ? Aebischer, P. (2005). Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse moDel of ALS. Nature Medicine, 11, 423-428. (Pubitemid 40562333)
75. Rettig, G. R., & Behlke, M.A. (2012). Progress toward in vivo use of siRNAs-II. Molecular Therapy, 20, 483-512.
76. Reynolds, A., Leake, D. , Boese, Q., Scaringe, S., Marshall, W., & Khvorova, A. (2004). Rational siRNA Design for RNA interference. Nature Biotechnology, 22, 326-330. (Pubitemid 38295766)
77. Reynolds, A., AnDerson, E., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., ? Khvorova, A. (2006). Induction of the interferon response by siRNA is cell type-and duplex lengthDepenDent. RNA, 12, 988-993. (Pubitemid 43788117)
78. Ryther R. C.,Flynt A.,Ha rris, B.,Phillips, J., III, ,Patton, J.,2004, GH1 splicing is regulated by multiple enhancers whose mutation produces a dominant-negative GH isoform that can be DegraDed by allele-specific small interfering RNA (siRNA, Journ al of Endocrinology,145,2988-2996. (Pubitemid 38686248)
79. Ryther, R. C., Flynt, A., Phillips, J., III, & Patton, J. (2005). siRNA therapeutics: Big potential from small RNAs. Gene Therapy, 12, 5-11. (Pubitemid 40090039)
80. Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N., Wolfsberg, T., Umayam, L., Lee, J., ? Collins, F. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proceedings of the National AcaDemy of Sciences, 101, 1892-1897. (Pubitemid 38228987)
81. Schwarz, D. S., Hutvá gner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199-208. (Pubitemid 37329583)
82. Semizarov, D., Frost, L., Sarthy, A., Kroeger, P., Halbert, D., & Fesik, S. (2003). Specificity of short interfering RNA Determined through gene exp ression signatures. Proceedings of the National AcaDemy of Sciences, 100, 6347-6352. (Pubitemid 36666584)
83. Shirane, D., Sugao, K., Namiki, S., Tanabe, M., Iino, M., & Hirose, K. (2004). Enzymatic production of RNAi libraries from cDNAs. Nature Genetics, 36, 190-196. (Pubitemid 38174380)
84. Simberg, D., Weisman, S., Talmon, Y., & Barenholz, Y. (2004). DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Critical Reviews in Therapeutic Drug Carrier Systems, 21, 257-317. (Pubitemid 41647579)
85. Sorensen, D. R., Leirdal, M., & Sioud, M. (2003). Gene silencing by systemic Delivery of synthetic siRNAs in adult mice. Journal of Molecular Biology, 327, 761-766. (Pubitemid 36315917)
86. Soutschek, J., Ak inc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., ? Vornlocher, H. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178. (Pubitemid 39545841)
87. Thakker, D. R., Natt, F., H üsken, D., Maier, R., Müller, M., Van Der Putten, H., Hoyer, D., & Cryan, J. (2004). Neurochemical and behavioral consequences of wiDespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proceedings of the National AcaDemy of Sciences, 101, 17270-17275. (Pubitemid 39627809)
88. Tiemann, K., & Rossi, J. J. (2009). RNAi-based therapeutics-current status, challenges and prospects. EMBO Molecular Medicine, 1, 142-151.
89. Tousignant, J. D., Gates, A., Ingram, L., Johnson, C., Nietupski, J., Cheng, S., ? Scheule, R. (2000). Comprehensive analysis of the acute toxicities induc ed by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum. Gene Ther., 11, 2493-2513.
90. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005). RNAi-med iated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy, 12, 461-466. (Pubitemid 40394299)
91. Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., ? Maraganore, J. (2010). A status report on RNAi therapeutics. Silence, 1, 14.
92. Victor, M. M., Xia, H., Marrs, G., Gouvion, C., Lee, G., Davidson, B., & Paulson, H. (2003). Allele-specific silencing of dominant disease genes. Proceedings of National AcaDemy of Science USA, 100, 7195-7200. (Pubitemid 36706415)
93. Wang, J., Lu, Z., & Guillaume, W. (2010). Delivery of siRNA therapeutics: Barriers and carriers. The AAPS Journal, 12, 492-503.
94. Weinstein, S., & Peer, D. (2010). RNAi nanomedicines: Challanges and opportunities within the immune system. Nanotechnology, 21, 1-13.
95. Yi, R., Qin, Y., Macara, I., & Cullen, B. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & Development, 17, 3011-3016. (Pubitemid 38040764)
96. Zhang, W., Yang, H., Kong, X., Mohapatra, S., San Juan-Vergara, H., Hellermann, G., ? Mohapatra, S. (2005). Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Medicine, 11, 56-62. (Pubitemid 40215838)
97. Zhao, L. N., Li, T., Pan, Y., Ning, H., Liu, Z., & Fan, D. (2005). Application of siRNA Lib rary in High-Throughput Genetic Screens of Mammalian Cells. Journal of Cancer Molecules, 1, 19-24.
98. Zhou, J., Shum, K., Burnett, J. C., & Rossi, J. (2013). Nanoparticle-based Delivery of RNAi therapeutics: Progress and challenges. Pharmaceuticals, 6, 85-107.